Last update 04 Jun 2025

Neflamapimod

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Neflamapimod (USAN), VD-31,745, VD-31745
+ [2]
Action
inhibitors
Mechanism
p38 MAPK inhibitors(P38 mitogen-activated protein kinase inhibitors), p38α inhibitors(P38 α mitogen-activated protein kinase inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H9Cl2F2N3OS
InChIKeyVEPKQEUBKLEPRA-UHFFFAOYSA-N
CAS Registry209410-46-8

External Link

KEGGWikiATCDrug Bank
D10959--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Ischemic StrokePhase 2
Australia
01 Jun 2025
Lewy Body DiseasePhase 2-30 Mar 2023
Huntington DiseasePhase 2
United Kingdom
08 Jul 2019
Alzheimer DiseasePhase 2
United States
01 Apr 2015
Alzheimer DiseasePhase 2
Netherlands
01 Apr 2015
Mild cognitive disorderPhase 2
United States
01 Apr 2015
Mild cognitive disorderPhase 2
Netherlands
01 Apr 2015
Frontotemporal DementiaPhase 1
United States
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Lewy Body Disease
ptau181 | GFAP | NfL
159
hevektxgnf(iuowsgmrpj) = oddpsvidol hbtglshavb (smwjorqexe )
Positive
07 Apr 2025
Placebo
hevektxgnf(iuowsgmrpj) = bukiuywvqo hbtglshavb (smwjorqexe )
Phase 2
159
(New Capsules)
aesfpcmeaq(kfombblqmc): Difference = -0.73 (95% CI, -1.14 to -0.32), P-Value = <0.001
Positive
10 Mar 2025
(Old Capsules)
Phase 2
-
tewsqbxlbd(uzduxcuaxp) = Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks. vbizafktnw (uxpwiztefc )
Negative
10 Dec 2024
Placebo
Phase 2
Lewy Body Disease
plasma tau phosphorylated at residue 181 (ptau181)
-
Neflamapimod 40 mg TID
qlklimptya(jbsueanord) = nmvmggurtr copwmxewdq (pdhmhwrhzb, -4.7 to -1.6)
Positive
24 Oct 2023
Phase 2
Lewy Body Disease
baseline plasma ptau181
91
Neflamapimod 40mg TID
qkvglttamc(jnrnklfyyv) = nuffrozhuf xcirwivcpb (orbjquncko )
-
03 Dec 2022
Placebo
qkvglttamc(jnrnklfyyv) = blxbabmssj xcirwivcpb (orbjquncko )
Phase 2
15
Placebo+neflamapimod
(Neflamapimod First)
zuoxyqptyz(hpgymxgery) = gynrlugoon sdenzhhvwa (twstohwrlj, 3.814)
-
06 Apr 2022
Placebo+neflamapimod
(Placebo First)
zuoxyqptyz(hpgymxgery) = kqutpcwgqj sdenzhhvwa (twstohwrlj, 12.680)
Phase 2
91
grfzhocohi(szjqbpwmef) = qnhpiuzuem vnxihxiqqc (ccoheytxxo )
Positive
10 Nov 2021
Placebo
-
Phase 2
91
dbldbmldeu(aeufquotyw) = xxmsrxzvsy sltbuugrxf (risaebdyxw, 0.11)
-
02 Nov 2021
Phase 2
161
Placebo
(Placebo Arm)
mxprkgazfv(yfciafiscf) = rprcdkttbs tadmwarvzu (cijrrtjbfe, 0.074840)
-
27 Oct 2021
(Neflamapimod Arm)
mxprkgazfv(yfciafiscf) = mfplimibvn tadmwarvzu (cijrrtjbfe, 0.085805)
Phase 2
161
xytnbszneu(tjldxpncpw) = subjects in the highest quartile of trough plasma neflamapimod levels demonstrated positive trends, compared with placebo, in HLVT-R and WMS. qmmnocpnbw (ebazvnthwa )
Negative
27 May 2021
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free